Results 71 to 80 of about 8,244 (227)

Platelets and galectins [PDF]

, 2014
A major function of platelets is keeping the vascular system intact. Platelet activation at sites of vascular injury leads to the formation of a hemostatic plug.
Schattner, Mirta Ana
core   +1 more source

A Critical Review on BH3 Mimetic Drugs and the Treatment of Cancer‐Associated Thrombosis (CAT): A Proposed Design for a Drug Delivery System Capable of Simultaneously Targeting Tumor Cells and Activated Platelets

Cancer Medicine, Volume 14, Issue 18, September 2025.
Targeting Cancer associated thrombosis (CAT): The left panel (A) shows cancer‐associated thrombosis with activated platelets expressing αIIbβ3 in close contact with tumoral vasculature expressing αvβ3 integrin, where both cells release a significant amount of thrombin.
Mehran Ghasemzadeh, Nazanin Heidari, Jalal Naghinezhad, Alireza Ghasemzadeh, Ehteramolsadat Hosseini   +4 more
wiley   +1 more source

P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity [PDF]

, 2014
Background: New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be used in combination with glycoprotein (GP) IIb‐IIIa antagonists, but their combined effect on platelet function and ...
Barnard, Marc R., Berny‐Lang, Michelle A., Frelinger, Andrew L., Jakubowski, Joseph A., Michelson, Alan D., Sugidachi, Atsuhiro   +5 more
core   +1 more source

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 470-479, August 2025.
P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Ashley N. Springer, Leah A. Alicea, Yemi Gafari, Tayler B. Smith, Sheryl Lynch, Amy M. Breman, Jennelle C. Hodge, Victoria M. Pratt, Nicholas R. Powell, Rolf P. Kreutz, Daniel P. Kobold, Michael T. Eadon, Emma M. Tillman, Tyler Shugg, Todd C. Skaar   +14 more
wiley   +1 more source

Comparison between Bolus Intracoronary versus Bolus Intravenous Injection Regimens of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Anterior ST-Segment Elevation Myocardial Infarction

Рациональная фармакотерапия в кардиологии, 2019
Background. Eptifibatide achieves high local concentration via direct intracoronary (I/V) injection as it promotes clot disaggregation, but it remains unclear if it is of superior benefit than the routine intravenous (I/V) administration. Aim.
Mohamed Hassan Nab, Shaimaa Mostafa, Khaled Elrabat, Hamza Kabil, Neama Elmelegy   +4 more
doaj   +1 more source

Platelets stop us leaking [PDF]

, 2016
In this issue of Blood, Welsh and colleagues determine how platelet thrombi limit the loss of plasma-borne proteins from the microvasculature. 1 The concept that platelets prevent leakage from blood vessels following a penetrating injury will come as ...
Bellido-Martín, Falati, Falati, Jonathan M. Gibbins, Law, Stalker, Stalker, Tomaiuolo, van Gestel, Welsh, Welsh   +10 more
core   +1 more source

High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction

British Journal of Pharmacology, Volume 182, Issue 16, Page 3838-3851, August 2025.
Abstract Background and Purpose The C‐type lectin‐like receptor‐2 (CLEC‐2) is a platelet receptor for the endogenous ligand podoplanin. This interaction contributes to several (patho)physiological processes, such as lymphangiogenesis, preservation of blood and lymphatic vessel integrity organ development, and tumour metastasis.
Marcin A. Sowa, Yan Wu, Jan van Groningen, Ying Di, Helma van den Hurk, Johannes A. Eble, Jonathan M. Gibbins, Ángel García, Alice Y. Pollitt   +8 more
wiley   +1 more source

Glycoprotein IIb/IIIa Receptor Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention

Рациональная фармакотерапия в кардиологии, 2020
Recently, there has been a positive trend to reduce mortality from myocardial infarction. One of the reasons for such dynamics is the development of angiographic service in our country and the increase in the number of primary percutaneous coronary ...
A. S. Tereshchenko, Е. V. Merkulov, A. M. Samko   +2 more
doaj   +1 more source

First Phosphonic‐Type Inhibitors and Activity‐Based Probes Specific to the O'nyong‐nyong Virus Capsid Protease

ChemMedChem, Volume 20, Issue 12, June 17, 2025.
The serine capsid protease (CP) catalyzes a crucial process of the alphaviral replication cycle; therefore, it constitutes an interesting therapy target. Herein, the O'nyong‐nyong virus CP profile activity with a specific fluorogenic substrate is analyzed and examines the inhibitory activity of a new series of phosphonic analogs of tryptophan and ...
Karolina Torzyk‐Jurowska, Agnieszka Łupicka‐Słowik, Renata Grzywa, Yuliya Chykunova, Krzysztof Pyrć, Marcin Sieńczyk   +5 more
wiley   +1 more source

A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules

Scientific Reports, 2022
A specific labeling strategy for bioactive molecules is presented for eptifibatide (integrilin) an antiplatelet aggregation inhibitor, which derives from the disintegrin protein barbourin in the venom of certain rattlesnakes. By specifically labeling the
Max Fleckenstein, Kevin Herr, Franziska Theiß, Stephan Knecht, Laura Wienands, Martin Brodrecht, Michael Reggelin, Gerd Buntkowsky   +7 more
doaj   +1 more source